Wilson Sonsini Goodrich & Rosati represented Forte Biosciences, while Paul Hastings advised TD Cowen in the transaction. Biopharmaceutical company, Forte Biosciences, announced an oversubscribed $53 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised General Atlantic on patent matters related to the transaction. Seaport Therapeutics (Seaport), a clinical-stage biopharmaceutical company that is advancing novel...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Avidity Biosciences on the deal, and Wilson Sonsini Goodrich & Rosati acted as patent counsel to Avidity. Avidity Biosciences, Inc. (Nasdaq: RNA),...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Avidity Biosciences, Inc. on the offering, and Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Cooley...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Avidity on patent matters related to the transaction. Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it has agreed to sell 15,224,773...
You must be a Standard 1 Year member to access this content.
